Find News

Filter articles

Applied Filters

Showing 61 to 70 of 232 results

Sumitomo sues over antipsychotic drug

India, Japan, US14-02-2018

Japan-based Sumitomo Dainippon Pharma has taken on Indian generics company Emcure Pharmaceuticals over an antipsychotic drug.

General Court dismisses Novartis trademark appeal

South Korea, Switzerland01-02-2018

The European General Court dismissed an appeal from Novartis over one of its figurative trademarks yesterday, January 31.

Abe & Partners makes two promotions


Japan-based Abe & Partners has promoted Michiko Kinoshita as partner and Tomohiro Kazama as counsel.

Sandoz enters into biosimilar partnership with Biocon

Germany, India, International22-01-2018

Germany-based Sandoz has entered into a partnership with Biocon to develop, manufacture and commercialise biosimilars in immunology and oncology.

MSF challenges Gilead patent application in China


Médecins Sans Frontières has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”. 

AstraZeneca forms Chinese company to boost innovation


AstraZeneca and the Chinese Future Industry Investment Fund have partnered to establish a company focused on discovering, developing and commercialising new medicines.

Sanofi leads the way for gene therapy patents: report


CPA Global has found that Sanofi files the most patents covering human gene therapy and also spends the most on them overall.

WIPO and pharma industry join forces to promote patent access


The World Intellectual Property Organization (WIPO) has partnered with trade group the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) to boost access to patent information.

Teva sells Paragard contraceptive for $1.1bn

Israel, US13-09-2017

Medical device firm Cooper Companies has agreed to acquire the global rights to Teva’s Paragard intrauterine device (IUD) for $1.1 billion.

AstraZeneca and Takeda enter agreement to develop Parkinson’s disease drug

Japan, UK29-08-2017

AstraZeneca and Takeda have entered into an agreement to develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease.

Showing 61 to 70 of 232 results